News

REGN Q1 Earnings Call: Pipeline Progress and EYLEA Headwinds Dominate Discussion
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...
Regeneron to buy bankrupt 23andMe for $256 million
Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...
BioSpace11h
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...
23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
Regeneron said Monday it will "prioritize the privacy, security and ethical use" of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt 23andMe ...
Ophthalmology Times4d
Q&A: Christine Kay, MD, gives an investigator's perspective on the PRISM clinical trial
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Bayer Stock Investment Could Pay Off, But It Is Not For The Faint Of Heart
Bayer A.G.'s stock is undervalued but faces risks with declining profits & regulatory pressures. Click for my updated look at ...
Notable analyst calls this week: Caterpillar, UnitedHealth and Peloton among top picks
Explore this week’s major market trends! S&P 500 closes mixed, with analyst calls on Warner Music, UnitedHealth, Caterpillar ...
pharmaphorum6d
Bayer CEO confident firm can cope with Xarelto hit
Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...
Investing6d
Regeneron at Bank of America Conference: Navigating Market Challenges
Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...